Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes.
CONCLUSION: Fanconi syndrome is a rare, exogenously acquired disorder in adults that often develops as an adverse effect of medication therapy. Our patient presented with Fanconi syndrome as a complication of canagliflozin use for the treatment of presumed type 2 diabetes. She was then started on subcutaneous insulin monotherapy for the treatment of type 1 diabetes mellitus.
PMID: 31724039 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Khan N, Tso K, Broussard J, Dziuba M Tags: Am J Health Syst Pharm Source Type: research
More News: Canagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Insulin | Invokana | Laboratory Medicine | Potassium | SGLT2 Inhibitors | Sodium | Urology & Nephrology